--- title: "MOTS-c vs SS-31 | PepTracker Pro" description: "MOTS-c and SS-31 both target mitochondrial function but through entirely different mechanisms — MOTS-c as an endogenous signaling peptide and SS-31 as a synthetic membrane-targeting compound." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "Article", "headline": "MOTS-c vs SS-31", "description": "MOTS-c and SS-31 both target mitochondrial function but through entirely different mechanisms — MOTS-c as an endogenous signaling peptide and SS-31 as a synthetic membrane-targeting compound.", "dateModified": "2026-07-17", "author": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "publisher": { "@type": "Organization", "name": "PepTracker Pro", "logo": { "@type": "ImageObject", "url": "https://peptrackerpro.com/favicon.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://peptrackerpro.com/compare/mots-c-vs-ss-31" } } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Compare](/compare)/ MOTS-c vs SS-31 **Research-only content.** This comparison is for educational purposes and does not constitute medical advice. [Read full disclaimer →](/research-disclaimer) # MOTS-c vs SS-31 Last updated: 2026-07-17 - MOTS-c is a mitochondrial-derived peptide encoded by mitochondrial DNA; SS-31 (Elamipretide) is a synthetic peptide that targets cardiolipin in the inner mitochondrial membrane. - MOTS-c research focuses on metabolic regulation and exercise mimetic effects; SS-31 research emphasizes mitochondrial dysfunction and cardioprotection. - SS-31 has advanced further in clinical trials, including Phase 2/3 studies for Barth syndrome and heart failure. - MOTS-c activates AMPK and influences glucose metabolism; SS-31 stabilizes the electron transport chain by binding cardiolipin. - Both represent a growing field of mitochondria-targeted peptide therapeutics. MOTS-c and SS-31 both target mitochondrial function but through entirely different mechanisms — MOTS-c as an endogenous signaling peptide and SS-31 as a synthetic membrane-targeting compound. ## Side-by-Side Comparison Attribute MOTS-c SS-31 What It Is A mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity. A mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic. Typical Research Focus MetabolismFat LossLongevityMuscle GrowthAnti-AgingEnergy LongevityAnti-AgingRecoveryNeuroprotection Proposed Mechanisms Not yet documented Not yet documented Evidence Snapshot Low Evidence research peptide High Evidence prescription drug Cautions - Discovery is recent; most data is preclinical - No completed human clinical trials - Long-term effects unknown - FDA-approved only for Barth syndrome; other indications remain investigational - Accelerated approval pathway — confirmatory trials may be required - Off-label use for anti-aging or longevity not supported by clinical evidence ### MOTS-c What It Is A mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity. Research Focus MetabolismFat LossLongevityMuscle GrowthAnti-AgingEnergy Evidence Low Evidence Cautions - Discovery is recent; most data is preclinical - No completed human clinical trials - Long-term effects unknown ### SS-31 What It Is A mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic. Research Focus LongevityAnti-AgingRecoveryNeuroprotection Evidence High Evidence Cautions - FDA-approved only for Barth syndrome; other indications remain investigational - Accelerated approval pathway — confirmatory trials may be required - Off-label use for anti-aging or longevity not supported by clinical evidence ## When Researchers Compare Them MOTS-c and SS-31 represent two distinct approaches to mitochondrial therapeutics. MOTS-c is an endogenous mitochondrial-derived peptide (MDP), meaning it is naturally encoded within mitochondrial DNA. Research has shown it activates AMPK, enhances glucose uptake, and may function as an exercise mimetic — making it a subject of interest in metabolic disease and aging research. SS-31 (also known as Elamipretide or Bendavia) is a synthetic tetrapeptide designed to penetrate cell membranes and selectively bind cardiolipin, a phospholipid critical to the inner mitochondrial membrane. By stabilizing the electron transport chain, SS-31 aims to restore mitochondrial efficiency in conditions where mitochondrial dysfunction is a driver of disease. SS-31 has progressed further in the clinical pipeline, with Phase 2 and 3 trials conducted in Barth syndrome, age-related macular degeneration, and heart failure with preserved ejection fraction. MOTS-c research remains primarily preclinical but is rapidly expanding. ## Peptide Profiles [MOTS-c Profile](/peptides/mots-c) [SS-31 Profile](/peptides/ss-31) ## Citations 1. \[1\] Lee C. et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab. 2015 [Source](https://pubmed.ncbi.nlm.nih.gov/) 2. \[2\] Lee C. et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab. 2015 [Source](https://pubmed.ncbi.nlm.nih.gov/25738459/) 3. \[3\] MOTS-c prevents pancreatic islet cell senescence to delay diabetes — Exp Mol Med. 2025 [Source](https://www.nature.com/articles/s12276-025-01521-1) 4. \[4\] MOTS-c restores mitochondrial respiration in type 2 diabetic heart — Frontiers Physiol. 2025 [Source](https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2025.1602271/full) 5. \[5\] MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline — Nature Commun. 2021 [Source](https://www.nature.com/articles/s41467-020-20790-0) 6. \[6\] MOTS-c in type 2 diabetes mellitus: From risk factors to cardiac complications — Life Sciences 2026 [Source](https://www.sciencedirect.com/science/article/abs/pii/S0024320525006459) 7. \[7\] FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee [Source](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) 8. \[8\] STAT — An obesity drug deep-dive, and peptides move mainstream (June 11, 2026) [Source](https://www.statnews.com/2026/06/11/an-obesity-drug-deep-dive-and-peptides-move-mainstream/) 9. \[9\] FDA Approves FORZINITY (elamipretide) for Barth Syndrome — Stealth BioTherapeutics, September 2025 [Source](https://stealthbt.com/stealth-biotherapeutics-announces-fda-accelerated-approval-of-forzinity-elamipretide-hcl/) 10. \[10\] UMDF — FDA Approves First Mitochondrial Disease Therapy [Source](https://umdf.org/fda-approves-elamipretide/) 11. \[11\] Johns Hopkins Hub — FDA approves drug for Barth syndrome, September 2025 [Source](https://hub.jhu.edu/2025/09/25/fda-approves-barth-syndrome-treatment/) 12. \[12\] Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential — IJMS. 2026 [Source](https://www.mdpi.com/1422-0067/26/3/944) 13. \[13\] SS-31 treatment ameliorates cardiac mitochondrial morphology in Barth syndrome model — Scientific Reports. 2024 [Source](https://www.nature.com/articles/s41598-024-64368-y) ### Explore Research Tools Use calculators for reconstitution, dosing references, and more. [Use PepTracker Pro Tools](/calculators) ## Related Peptides ### 5-Amino-1MQ Low Evidence A small molecule NNMT inhibitor studied for metabolic enhancement and fat cell reduction. [Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Energy](/benefits/energy) [View Details](/peptides/5-amino-1mq) [\+ Compare](/compare?select=5-amino-1mq)[](https://app.peptrackerpro.com/?add=5-amino-1mq) ### Epithalon Low Evidence A tetrapeptide studied for its potential to activate telomerase and influence biological aging markers. [Longevity](/benefits/longevity)[Anti-Aging](/benefits/anti-aging)[Sleep](/benefits/sleep)[Immune Support](/benefits/immune-support) [View Details](/peptides/epithalon) [\+ Compare](/compare?select=epithalon)[](https://app.peptrackerpro.com/?add=epithalon) ### Humanin Low Evidence An endogenous mitochondrial-derived peptide studied for neuroprotection, cellular stress resistance, and longevity, whose blood levels fall with age and are elevated in centenarians. [Longevity](/benefits/longevity)[Anti-Aging](/benefits/anti-aging)[Neuroprotection](/benefits/neuroprotection)[Metabolism](/benefits/metabolism)+2 more [View Details](/peptides/humanin) [\+ Compare](/compare?select=humanin)[](https://app.peptrackerpro.com/?add=humanin) ### Motixafortide (Aphexda) High Evidence An FDA-approved synthetic cyclic peptide and CXCR4 antagonist (brand name Aphexda; research name BL-8040) used together with G-CSF to mobilize blood-forming stem cells for autologous transplant in multiple myeloma. In 2026 it is being actively studied as part of combination immunotherapy for pancreatic cancer. [stem-cell-mobilization](/benefits/stem-cell-mobilization)[oncology](/benefits/oncology)[immune-modulation](/benefits/immune-modulation)[transplant-support](/benefits/transplant-support) [View Details](/peptides/motixafortide) [\+ Compare](/compare?select=motixafortide)[](https://app.peptrackerpro.com/?add=motixafortide) ### NAD+ Medium Evidence A coenzyme essential for cellular energy production, studied for anti-aging and metabolic support. [Energy](/benefits/energy)[Longevity](/benefits/longevity)[Anti-Aging](/benefits/anti-aging)[Metabolism](/benefits/metabolism)+1 more [View Details](/peptides/nad) [\+ Compare](/compare?select=nad)[](https://app.peptrackerpro.com/?add=nad) ### SLU-PP-332 Low Evidence A synthetic ERRα/β/γ pan-agonist studied as an 'exercise mimetic' for endurance, fat oxidation, and metabolic health. [endurance](/benefits/endurance)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Energy](/benefits/energy) [View Details](/peptides/slu-pp-332) [\+ Compare](/compare?select=slu-pp-332)[](https://app.peptrackerpro.com/?add=slu-pp-332) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.